Literature DB >> 12617561

Glial proinflammatory cytokines mediate exaggerated pain states: implications for clinical pain.

Linda R Watkins1, Erin D Milligan, Steven F Maier.   

Abstract

When you hurt yourself, you become consciously aware of the pain because a chain of neurons carries the pain message from the injury to the spinal cord, and then from the spinal cord up to consciousness in the brain. However, it has been known for more than two decades that neural circuits within the spinal cord can cause your conscious experience of pain to be amplified-that is, the pain you perceive is out of proportion to the injury that caused it. Until now, all research aimed at understanding how pain amplification occurs in the spinal cord and all drug therapies aimed at curing exaggerated pain have focused exclusively on neurons. This is because neurons were the only type of cell believed to be important in pain. The present review argues that neurons in fact are not the only cell type involved. Rather, that spinal cord cells called "glia" are also critically important. Indeed, when glia become activated, they begin releasing a variety of chemical substances that causes the pain message to become amplified, thus causing pain to hurt more. This review discusses evidence that glia cause pain to become amplified and describes how the glia cause this to happen. The take-home message is that drugs that target glia and the chemical substances that these glia release are predicted to be powerful remedies for pain problems in people.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12617561

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  95 in total

Review 1.  Role of microglia in central nervous system infections.

Authors:  R Bryan Rock; Genya Gekker; Shuxian Hu; Wen S Sheng; Maxim Cheeran; James R Lokensgard; Phillip K Peterson
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

2.  Flurbiprofen axetil reduces postoperative sufentanil consumption and enhances postoperative analgesic effects in patients with colorectal cancer surgery.

Authors:  Xue Lin; Ruiqin Zhang; Jingchun Xing; Xiaocui Gao; Pan Chang; Wenzhi Li
Journal:  Int J Clin Exp Med       Date:  2014-12-15

Review 3.  Cytokines, inflammation, and pain.

Authors:  Jun-Ming Zhang; Jianxiong An
Journal:  Int Anesthesiol Clin       Date:  2007

4.  The multiple benefits of minimally invasive spinal surgery: results comparing transforaminal lumbar interbody fusion and posterior lumbar fusion.

Authors:  Angela R Starkweather; Linda Witek-Janusek; Russ P Nockels; Jonna Peterson; Herb L Mathews
Journal:  J Neurosci Nurs       Date:  2008-02       Impact factor: 1.230

Review 5.  Long-term control of neuropathic pain in a non-viral gene therapy paradigm.

Authors:  E M Sloane; R G Soderquist; S F Maier; M J Mahoney; L R Watkins; E D Milligan
Journal:  Gene Ther       Date:  2009-03-05       Impact factor: 5.250

6.  Understanding fibromyalgia and its related disorders.

Authors: 
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2008

7.  Substance P spinal signaling induces glial activation and nociceptive sensitization after fracture.

Authors:  W-W Li; T-Z Guo; X Shi; Y Sun; T Wei; D J Clark; W S Kingery
Journal:  Neuroscience       Date:  2015-09-16       Impact factor: 3.590

8.  Psychologic and biologic factors associated with fatigue in patients with persistent radiculopathy.

Authors:  Angela Starkweather
Journal:  Pain Manag Nurs       Date:  2010-12-30       Impact factor: 1.929

Review 9.  Pathophysiology of fibromyalgia.

Authors:  Laurence A Bradley
Journal:  Am J Med       Date:  2009-12       Impact factor: 4.965

10.  Immunological priming potentiates non-viral anti-inflammatory gene therapy treatment of neuropathic pain.

Authors:  E Sloane; S Langer; B Jekich; J Mahoney; T Hughes; M Frank; W Seibert; G Huberty; B Coats; J Harrison; D Klinman; S Poole; S Maier; K Johnson; R Chavez; L R Watkins; L Leinwand; E Milligan
Journal:  Gene Ther       Date:  2009-07-02       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.